287 related articles for article (PubMed ID: 34220801)
21. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
22. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer.
Su S; Lin A; Luo P; Zou J; Huang Z; Wang X; Zeng Y; Cen W; Zhang X; Huang H; Hu J; Zhang J
Ann Transl Med; 2021 Sep; 9(18):1475. PubMed ID: 34734027
[TBL] [Abstract][Full Text] [Related]
23. Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma.
Hong S; Zhang Y; Cao M; Lin A; Yang Q; Zhang J; Luo P; Guo L
Front Cell Dev Biol; 2021; 9():762478. PubMed ID: 34901008
[No Abstract] [Full Text] [Related]
24. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
25. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
26. Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.
Lin A; Qiu Z; Zhang J; Luo P
Front Immunol; 2021; 12():630773. PubMed ID: 33763074
[TBL] [Abstract][Full Text] [Related]
27. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.
Lou S; Wang Y; Zhang J; Yin X; Zhang Y; Wang Y; Xue Y
Front Immunol; 2021; 12():806324. PubMed ID: 35082793
[TBL] [Abstract][Full Text] [Related]
28. A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint blockade therapy.
Lin J; Ding M; Qin C; Song Y; Yang W; Du Y; Xu T
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9877-9890. PubMed ID: 37247083
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
Lee HW; Seo HK
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502435
[TBL] [Abstract][Full Text] [Related]
30. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
31. ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment.
Yi R; Lin A; Cao M; Xu A; Luo P; Zhang J
Front Genet; 2020; 11():933. PubMed ID: 32922441
[TBL] [Abstract][Full Text] [Related]
32. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
33. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Ferro M; Crocetto F; Tataru S; Barone B; Dolce P; Lucarelli G; Sonpavde G; Musi G; Antonelli A; Veccia A; Terracciano D; Busetto GM; Del Giudice F; Marchioni M; Schips L; Porpiglia F; Fiori C; Carrieri G; Lasorsa F; Verde A; Scafuri L; Buonerba C; Di Lorenzo G
Clin Genitourin Cancer; 2023 Oct; 21(5):574-583. PubMed ID: 37419854
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
[TBL] [Abstract][Full Text] [Related]
36. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
37. Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinoma.
Hou S; Gu T; Shi Y; Huang Y; Yao J; Luo P; Cao M; Zhang J; Lin A; Zhu W
Cancer Biomark; 2023; 38(4):489-504. PubMed ID: 38043008
[TBL] [Abstract][Full Text] [Related]
38. Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
Gong Z; He Y; Mi X; Li C; Sun X; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Wang L; Liu Z
Aging (Albany NY); 2023 Sep; 15(18):9479-9498. PubMed ID: 37747262
[TBL] [Abstract][Full Text] [Related]
39. DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma.
Chen M; Huang B; Zhu L; Wang Q; Pang Y; Cheng M; Lian H; Liu M; Zhao K; Xu S; Zhang J; Zhong C
Front Immunol; 2022; 13():875648. PubMed ID: 35720326
[TBL] [Abstract][Full Text] [Related]
40. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
